

Arguments/Remarks

Claims 1-4 and 9-10 were pending in the instant application.

Claims 1 to 3 have been amended as suggested by the Examiner during the phone interview of May 18, 2009. No new matter has been added.

Applicants note with appreciation that the Examiner has indicated that the above amendments will place the present application in good condition for allowance.


CONCLUSION

If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

If necessary, the Commissioner is hereby authorized to charge payment to Deposit Account No. 50-4409 for any additional fees under 37 C.F.R. 1.16 or under 37 C.F.R. 1.17.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Ave
Cambridge, MA 02139
(617) 871-4125


Mark Milstead
Attorney for Applicants
Reg. No. 45,825

Date: *May 18, 2009*